Stockreport

Akari Therapeutics’ Nomacopan Demonstrates Positive Early Safety and Efficacy in Phase I/II Clinical Study in Moderate-to-Severe Atopic Keraconjunctivitis (AKC)

Akari Therapeutics Plc - American Depositary Shares  (AKTX) 
US:NASDAQ Investor Relations: investor.akaritx.com/investor-relations
PDF Part A of a safety and efficacy study successfully completed with nomacopan eye drops which were well tolerated with no serious adverse events.Improvement in mean compos [Read more]